Biotech pursuing deal to access $5B China market with lung cancer test
San Antonio-based bioAffinity Technologies Inc. has secured a non-binding letter of intent from Shanghai Fosun Long March Medical Science Co. Ltd. to evaluate its initial product — the CyPath Lung.
The expectation is that the two companies will negotiate a binding agreement to commercialize the non-invasive test for early detection of lung cancer in China.
“China represents a $5 billio n market for CyPath Lung. An estimated 780,000 people will be diagnosed annually in China with lung cancer,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: W. Scott Bailey Source Type: news
More News: Biomedical Science | Biotechnology | Cancer | Cancer & Oncology | China Health | Health Management | Lung Cancer | Science